Skip to content

Search

Feasibility of 24-hour hybrid closed loop insulin delivery in free living conditions

The aim of this study is to see if the Medtronic hybrid closed loop system, a portable artificial pancreas is feasibly to use in the home.

Closed Loop Study - Multicentre

A Closed-Loop System will potentially have a major impact upon acute and chronic complications of diabetes as well as upon their quality of life

Predictive low glucose suspend study – Randomised Controlled trial

Testing a feature of the MiniMed 640G insulin pump, which when used together with a real-time continuous glucose sensor can suspend and resume insulin delivery

How do high protein and/or high fat meals affect postprandial glycaemic control in children using intensive insulin therapy?

Investigating the effect of fat and protein content of a standardised carbohydrate meal on the post-prandial glycaemic response in children with type 1 diabetes

TrialNet: Pathway to Prevention

This study is helping us to learn how type 1 diabetes develop and ways to delay and prevent it.

Using continuous glucose monitoring to detect early dysglycaemia in children participating in the ENDIA study (Sub Protocol)

Aveni Liz Haynes Davis BA (Hons), MBBChir, MA (Cantab), PhD MBBS FRACP PhD Principal Research Fellow Co-director of Children’s Diabetes Centre

Experiences and Attitudes of Parents Reducing Carbohydrate Intake in the Management of Their Child’s Type 1 Diabetes: A Qualitative Study

Reducing carbohydrate (CHO) intake is being used as an approach to manage type 1 diabetes (T1D) in children. This study aimed to investigate the experiences and attitudes of parents of children with T1D who are reducing CHO intake to help manage blood glucose levels.

Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in Australia and New Zealand

Islet autoantibody screening of infants and young children in the Northern Hemisphere, together with semi-annual metabolic monitoring, is associated with a lower risk of ketoacidosis (DKA) and improved glucose control after diagnosis of clinical (stage 3) type 1 diabetes (T1D). We aimed to determine if similar benefits applied to older Australians and New Zealanders monitored less rigorously.

An Assessment of Clinical Continuous Glucose Monitoring Targets for Older and High-Risk People Living with Type 1 Diabetes

To assess relationships between continuous glucose monitoring (CGM) time in range (TIR), 70-180 mg/dL, time below range (TBR), <70 mg/dL, time above range (TAR), >180 mg/dL, and glucose coefficient of variation (CV) in relation to currently recommended clinical CGM targets for older people, which recommend reduced TIR and TBR targets relative to the general type 1 diabetes population.